Paris and Lyon, October 22, 2018 – ORPHELIA Pharma, a French biopharmaceutical company dedicated to the development and marketing of pediatric drugs in the fields of oncology and neurology, announces today that it has obtained the support of Bpifrance through a ERDF (European Regional Development Fund) innovation loan of one million Euros co-financed by the European Union and the Auvergne Rhône-Alpes region. This grant aims to support the development and industrialization of the first pediatric formulation of an essential drug as a salvage therapy of a rare pediatric cancer. “We are delighted to receive the support from Bpifrance which allows us to accelerate the development of our product in this pediatric indication whose unmet medical need is huge“, comments Jérémy Bastid, Chief Development Officer of ORPHELIA Pharma. “This product has a formulation specially adapted for young children and has been developed in close collaboration with clinicians since 2017. This grant will contribute to the development cost of the product until it becomes available to patients in 2 to 3 years“, adds Hugues Bienaymé, General Manager.
About ORPHELIA Pharma
Based in Paris and Lyon, ORPHELIA Pharma SAS is a French biopharmaceutical company dedicated to the development and marketing of oncology and neurology pediatric drugs. Its mission is to significantly improve essential medicines administered to children through the development of efficient, reliable and safe drugs with child-friendly formulations. ORPHELIA Pharma also leads innovative R&D projects through academic and industrial partnerships. Key investors include initiative OCTALFA (lead investor) and Pierre Fabre Medicament.